{
  EUADR_drug_disease : 
    {
      1 : 
        {
          1 : "NN nmod NN nmod NN"
          2 : 4
          3 : 
            {
              1 : "drug0 nmod *use* nmod drug0"
              2 : "drug0 nmod *development* nmod drug0"
              3 : "drug0 nmod year nmod *drug0*"
              4 : "drug0 nmod *risk* nmod drug0"
            }
          4 : 
            {
              1 : "Information from the SITE Cohort Study should clarify whether use of these drug1 for drug2 increases the risk of mortality and fatal cancer . "
              2 : "Development of drug1 in drug2 - treated rheumatoid arthritis patients . "
              3 : "The other developed drug1 and a plaque lesion on the right arm after 1 year of drug2 . "
              4 : "There was an estimated 50 % excess risk of drug1 among drug2 - exposed RA patients relative to the general population ( SIR 1.5 , 95 % confidence interval [ 95 % CI ] 1.2-1 .9 ) , with a 3-fold increase in melanoma ( SIR 3.0 , 95 % CI 1.2-6 .2 ) , a 5-fold increase in non-Hodgkin 's lymphoma ( SIR 5.1 , 95 % CI 2.2-10 .0 ) , and an almost 3-fold increase in lung cancer ( SIR 2.9 , 95 % CI 1.6-4 .8 ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
              4 : 1
            }
        }
      2 : 
        {
          1 : "NN nmod NN nmod NN nmod NN"
          2 : 3
          3 : 
            {
              1 : "drug0 nmod prophylaxis nmod *use* nmod drug0"
              2 : "drug0 nmod prevention nmod *alternative* nmod drug0"
              3 : "drug0 nmod prophylaxis nmod *generation* nmod drug0"
            }
          4 : 
            {
              1 : "Recent prospective studies from Europe suggest the use of intracameral drug1 for prophylaxis of drug2 , although the studies did not make a comparison with the most common United States prophylaxis techniques . "
              2 : "Our data showed that oxcarbazepine can be a good alternative to traditional drug1 in the prevention of drug2 being efficacy , ease of use ( rapid titration in 3 days , not requiring close plasma concentration monitoring ) and good tolerability ( no major side effects during titration and during the first postoperative week ) the key factors . "
              3 : "Furthermore , the efficacy of the new generation of drug1 in the prophylaxis of drug2 has not been assessed so far . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      3 : 
        {
          1 : "NN compound NNS nmod NNS nmod VBN nsubjpass NN nmod NNS conj NN"
          2 : 3
          3 : 
            {
              1 : "drug0 compound patients nmod records nmod *ascertained* nsubjpass use nmod antimetabolites conj drug0"
              2 : "drug0 compound patients nmod records nmod *ascertained* nsubjpass use nmod antimetabolites conj drug0"
              3 : "drug0 compound patients nmod records nmod *ascertained* nsubjpass use nmod antimetabolites conj drug0"
            }
          4 : 
            {
              1 : "Past use of antimetabolites , T-cell inhibitors , drug1 , and other immunosuppressives is ascertained from medical records of approximately 9,250 drug2 patients at five tertiary centers over up to 30 years . "
              2 : "Past use of antimetabolites , drug1 , alkylating agents , and other immunosuppressives is ascertained from medical records of approximately 9,250 drug2 patients at five tertiary centers over up to 30 years . "
              3 : "Past use of antimetabolites , T-cell inhibitors , alkylating agents , and other drug1 is ascertained from medical records of approximately 9,250 drug2 patients at five tertiary centers over up to 30 years . "
            }
          5 : 
            {
              1 : 1
              2 : 1
              3 : 1
            }
        }
      4 : 
        {
          1 : "NN conj NN nmod NN nmod VBZ nsubj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj disease nmod evidence nmod *decreases* nsubj drug0"
              2 : "drug0 conj disease nmod evidence nmod *decreases* nsubj drug0"
            }
          4 : 
            {
              1 : "Compared with both diuretics and contemporary agents , drug1 decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease , gastrointestinal bleeding or drug2 . "
              2 : "Compared with both diuretics and contemporary agents , drug1 decreases cardiovascular events to a similar or greater extent without evidence for increased coronary heart disease , drug2 or cancer . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      5 : 
        {
          1 : "NN nmod VBN acl NN"
          2 : 2
          3 : 
            {
              1 : "drug0 nmod treated acl *drug0*"
              2 : "drug0 nmod treated acl *drug0*"
            }
          4 : 
            {
              1 : "This article reviewed recent results from randomized , double-blind studies of children with drug1 treated with drug2 , a leukotriene receptor antagonist that is approved for the treatment of asthma and allergic rhinitis in children and adults . "
              2 : "Sustained virologic response ( SVR ) rates of 50 % -60 % have been achieved in patients with drug1 treated with drug2 plus ribavirin . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      6 : 
        {
          1 : "NN compound NNS nmod NN"
          2 : 2
          3 : 
            {
              1 : "drug0 compound controls nmod *drug0*"
              2 : "drug0 nmod *effects* compound drug0"
            }
          4 : 
            {
              1 : "An inverse trend was observed between dose and multiplicity of colonic dysplasias in all drug-treated groups ( P = 0.03 ) , with animals receiving 75 mg/kg 5-ASA exhibiting 56 % of the number of drug1 of the AOM / drug2 controls ( mean + / - SEM : 7.6 + / - 1.4 and 13.6 + / - 2.7 , respectively ) . "
              2 : "The reasons for conversion were calcineurin inhibitors ( CNI ) nephrotoxicity ( n = 24 ; 73 % ) , severe neurotoxicity owing to CNI ( n = 1 ; 3 % ) , severe and/or recurrent acute rejection episodes ( n = 7 ; 21 % ) , drug1 ( GI ) side effects of drug2 ( MMF ; n = 5 ; 15 % ) , and hyperglycemia ( n = 4 ; 12 % ) . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      7 : 
        {
          1 : "NN conj NN nmod NNS dobj VBD dep NNS dep VBG dobj NN"
          2 : 2
          3 : 
            {
              1 : "drug0 conj dyspnoea nmod complaints dobj *presented* dep years dep initiating dobj drug0"
              2 : "drug0 conj dyspnoea nmod complaints dobj *presented* dep years dep initiating dobj drug0"
            }
          4 : 
            {
              1 : "Two years after initiating drug1 , she presented complaints of progressive dyspnoea , drug2 , chest pain and low-grade fever of 1 month duration . "
              2 : "Two years after initiating drug1 , she presented complaints of progressive dyspnoea , nonproductive cough , drug2 and low-grade fever of 1 month duration . "
            }
          5 : 
            {
              1 : 1
              2 : 1
            }
        }
      8 : 
        {
          1 : "NN conj NNP dobj VBG conj NN nmod VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj crp dobj regarding conj mitigation nmod *observed* nmod drug0"
            }
          4 : 
            {
              1 : "No significant differences were observed between drug1 + citrate and NaFe-EDTA fortification , regarding mitigation of iron-deficiency anemia ( IDA ) or regarding CRP , growth , drug2 , or side-effects . "
            }
          5 : 
            {
              1 : 1
            }
        }
      9 : 
        {
          1 : "NN dobj VB csubj VBG nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *cause* csubj occurring nsubj exposure nmod drug0"
            }
          4 : 
            {
              1 : "Exposure to drug1 occurring in medical practice may cause drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      10 : 
        {
          1 : "NN nmod NN nmod VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod mitigation nmod *observed* nmod drug0"
            }
          4 : 
            {
              1 : "No significant differences were observed between drug1 + citrate and NaFe-EDTA fortification , regarding mitigation of drug2 ( IDA ) or regarding CRP , growth , infections , or side-effects . "
            }
          5 : 
            {
              1 : 1
            }
        }
      11 : 
        {
          1 : "NN compound NNS nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound inhibitors nmod associated acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 associated with drug2 -2 selective inhibitors and nonselective antiinflammatory drugs . "
            }
          5 : 
            {
              1 : 1
            }
        }
      12 : 
        {
          1 : "NN nmod NN dobj VBD nsubj NNS acl VBN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod rate dobj *experienced* nsubj women acl exposed nmod drug0"
            }
          4 : 
            {
              1 : "Women exposed to drug1 experienced at least a threefold higher rate of drug2 than those exposed to X-ray ( OR = 3.68 , 95 % CI = 1.39-9 .74 , P < 0.01 ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      13 : 
        {
          1 : "NN appos NN nmod VB xcomp VBN nsubjpass NN nmod NNS appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos example nmod contribute xcomp *suggested* nsubjpass exposure nmod benzodiazepines appos drug0"
            }
          4 : 
            {
              1 : "Exposure to Benzodiazepines ( drug1 ) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations , for example , drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      14 : 
        {
          1 : "NN nmod NN nmod VBN nmod NN conj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod mitigation nmod *observed* nmod feso0 conj fortification compound drug0"
            }
          4 : 
            {
              1 : "No significant differences were observed between FeSO4 + citrate and drug1 fortification , regarding mitigation of drug2 ( IDA ) or regarding CRP , growth , infections , or side-effects . "
            }
          5 : 
            {
              1 : 1
            }
        }
      15 : 
        {
          1 : "NN dobj VBD nsubj NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *showed* nsubj users compound drug0"
            }
          4 : 
            {
              1 : "After two years drug1 users showed persistent drug2 , working memory and processing speed . "
            }
          5 : 
            {
              1 : 1
            }
        }
      16 : 
        {
          1 : "NN conj NNP dobj VBG conj NN nmod VBN nmod NN conj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj crp dobj regarding conj mitigation nmod *observed* nmod feso0 conj fortification compound drug0"
            }
          4 : 
            {
              1 : "No significant differences were observed between FeSO4 + citrate and drug1 fortification , regarding mitigation of iron-deficiency anemia ( IDA ) or regarding CRP , growth , drug2 , or side-effects . "
            }
          5 : 
            {
              1 : 1
            }
        }
      17 : 
        {
          1 : "NN dobj VBD advcl VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *showed* advcl classified nmod use nmod drug0"
            }
          4 : 
            {
              1 : "When ecstasy users were classified according to lifetime use of drug1 , the more severe users ( more than 100 tablets ) showed additional drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      18 : 
        {
          1 : "NN dobj VBG acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj requiring acl *drug0*"
            }
          4 : 
            {
              1 : "Primary outcomes were drug1 ( AE ) requiring systemic drug2 or hospitalization , life-threatening exacerbations and asthma-related deaths . "
            }
          5 : 
            {
              1 : 1
            }
        }
      19 : 
        {
          1 : "NN nmod NN nmod VBP dobj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod prevention nmod *require* dobj medication compound drug0"
            }
          4 : 
            {
              1 : "Children with prosthetic cardiac valves and other invasive mechanical devices that direct blood flow require drug1 medication for prevention of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      20 : 
        {
          1 : "NN nmod VB acl:relcl NN nmod RB advmod VBG conj VBG dobj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod result acl:relcl procedure nmod prior advmod instituting conj *decreasing* dobj drug0"
            }
          4 : 
            {
              1 : "Dental surgery for these children has historically consisted of decreasing and/or discontinuing the oral drug1 and instituting heparin therapy prior to the planned dental procedure , which can result in drug2 and increased morbidity and mortality . "
            }
          5 : 
            {
              1 : 1
            }
        }
      21 : 
        {
          1 : "NN nmod NN nmod NN dobj VBP acl:relcl NNS dobj VBP nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod management nmod consideration dobj merit acl:relcl attributes dobj *have* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 have several noteworthy attributes that merit consideration in the management of drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      22 : 
        {
          1 : "NN nmod NN nmod VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod evidence nmod *decreases* nsubj drug0"
            }
          4 : 
            {
              1 : "Compared with both diuretics and contemporary agents , drug1 decreases cardiovascular events to a similar or greater extent without evidence for increased drug2 , gastrointestinal bleeding or cancer . "
            }
          5 : 
            {
              1 : 1
            }
        }
      23 : 
        {
          1 : "NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *drug0*"
            }
          4 : 
            {
              1 : "The established drug1 of drug2 raises important issues in women of child-bearing age . "
            }
          5 : 
            {
              1 : 1
            }
        }
      24 : 
        {
          1 : "NN compound NN nmod NN dobj VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound conversion nmod status dobj *showed* nsubj patient nmod drug0"
            }
          4 : 
            {
              1 : "The only patient with drug1 showed improved neurologic status after drug2 conversion . "
            }
          5 : 
            {
              1 : 1
            }
        }
      25 : 
        {
          1 : "NN nmod NNS nmod NN nmod VBN nsubjpass NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod patients nmod anticoagulant nmod *used* nsubjpass drug0"
            }
          4 : 
            {
              1 : "drug1 is used as an alternative anticoagulant , particularly in patients with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      26 : 
        {
          1 : "NN nmod VBP acl:relcl NNS dobj VB nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod protect acl:relcl effects dobj *exert* nsubj drug0"
            }
          4 : 
            {
              1 : "drug1 may exert effects that protect against drug2 that are independent of their blood pressure-lowering mechanism . "
            }
          5 : 
            {
              1 : 1
            }
        }
      27 : 
        {
          1 : "NN nmod NNS nmod NN nmod NN dep JJ amod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod patients nmod efficacy nmod review dep weekly amod *drug0*"
            }
          4 : 
            {
              1 : "drug1 once weekly : review of its efficacy and safety in patients with chemotherapy-induced drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      28 : 
        {
          1 : "NN nmod NNS nmod NN nmod VBZ nsubj NN nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod patients nmod hypertension nmod *associates* nsubj exposure nmod therapy compound drug0"
            }
          4 : 
            {
              1 : "Long-term exposure to drug1 therapy associates with hypertension in patients with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      29 : 
        {
          1 : "NN nmod NN dobj VB nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod risk dobj *increase* nsubj use nmod drug0"
            }
          4 : 
            {
              1 : "Maternal use of drug1 and/or HBRA may increase the risk for drug2 and low birth weight and cause neonatal symptoms , but does not appear to have a strong teratogenic potential . "
            }
          5 : 
            {
              1 : 1
            }
        }
      30 : 
        {
          1 : "NN nmod NNS nmod NN nmod NN dobj VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod patients nmod survival nmod effect dobj *has* nsubj drug0"
            }
          4 : 
            {
              1 : "This once-weekly regimen is generally well tolerated , and studies to date have reported that drug1 has a neutral effect on survival of patients with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      31 : 
        {
          1 : "NN conj NN nmod VB xcomp VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj morbidity nmod contribute xcomp *suggested* nsubjpass exposure nmod drug0"
            }
          4 : 
            {
              1 : "Exposure to drug1 ( BZD ) during foetal life has been suggested to contribute to neonatal morbidity and some drug2 , for example , orofacial clefts . "
            }
          5 : 
            {
              1 : 1
            }
        }
      32 : 
        {
          1 : "NN conj NN nmod VB xcomp VBN nsubjpass NN nmod NNS appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj morbidity nmod contribute xcomp *suggested* nsubjpass exposure nmod benzodiazepines appos drug0"
            }
          4 : 
            {
              1 : "Exposure to Benzodiazepines ( drug1 ) during foetal life has been suggested to contribute to neonatal morbidity and some drug2 , for example , orofacial clefts . "
            }
          5 : 
            {
              1 : 1
            }
        }
      33 : 
        {
          1 : "NN dep NN nmod NNS compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep mofetil nmod *effects* compound drug0"
            }
          4 : 
            {
              1 : "The reasons for conversion were calcineurin inhibitors ( CNI ) nephrotoxicity ( n = 24 ; 73 % ) , severe neurotoxicity owing to CNI ( n = 1 ; 3 % ) , severe and/or recurrent acute rejection episodes ( n = 7 ; 21 % ) , drug1 ( GI ) side effects of mycophenolate mofetil ( drug2 ; n = 5 ; 15 % ) , and hyperglycemia ( n = 4 ; 12 % ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      34 : 
        {
          1 : "NN nmod NNS nmod NN nmod NN nmod NNS nmod NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod children nmod monotherapy nmod *review* nmod results nmod use compound drug0"
            }
          4 : 
            {
              1 : "Review of recent results of drug1 use as a monotherapy in children with drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      35 : 
        {
          1 : "NN appos NN nmod NNS conj NNS conj NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos a nmod patients conj *individuals* conj patients nmod drug0"
            }
          4 : 
            {
              1 : "Gingival samples were collected from eight normal healthy individuals , eight patients with drug1 , and eight patients with cyclosporin A ( drug2 ) - induced gingival overgrowth . "
            }
          5 : 
            {
              1 : 1
            }
        }
      36 : 
        {
          1 : "NN compound NNS nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound lines nmod *effects* nmod drug0"
            }
          4 : 
            {
              1 : "The aim of this study was to evaluate the effects of drug1 and indomethacin ethyl ester-loaded nanocapsules on drug2 cell lines . "
            }
          5 : 
            {
              1 : 1
            }
        }
      37 : 
        {
          1 : "NN compound NNS nmod NN nmod NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound lines nmod *cytotoxicity* nmod indomethacin conj drug0"
            }
          4 : 
            {
              1 : "Selective cytotoxicity of indomethacin and drug1 against drug2 cell lines : an in vitro study . "
            }
          5 : 
            {
              1 : 1
            }
        }
      38 : 
        {
          1 : "NN compound NNS nmod NNS nmod VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound patients nmod records nmod *ascertained* nsubjpass use nmod drug0"
            }
          4 : 
            {
              1 : "Past use of drug1 , T-cell inhibitors , alkylating agents , and other immunosuppressives is ascertained from medical records of approximately 9,250 drug2 patients at five tertiary centers over up to 30 years . "
            }
          5 : 
            {
              1 : 1
            }
        }
      39 : 
        {
          1 : "NN nmod NNS nmod NN dep JJR nmod NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod patients nmod overgrowth dep *higher* nmod patients nmod drug0"
            }
          4 : 
            {
              1 : "ET-1 mRNA expression was significantly higher in patients with drug1 - induced gingival overgrowth ( P < 0.001 ) than in patients with drug2 and the controls . "
            }
          5 : 
            {
              1 : 1
            }
        }
      40 : 
        {
          1 : "NN conj NN nmod NN conj NN conj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj ponv nmod history conj gender conj *alfentanil* conj drug0"
            }
          4 : 
            {
              1 : "The frequency of PONV did not correlate to the amounts of alfentanil , drug1 , postoperative antiemetics consumed , or to female gender , non-smoking status , and history of PONV or drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      41 : 
        {
          1 : "NN dep VBN nmod NNS conj NNS nmod NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep *collected* nmod individuals conj patients nmod a appos drug0"
            }
          4 : 
            {
              1 : "Gingival samples were collected from eight normal healthy individuals , eight patients with periodontitis , and eight patients with cyclosporin A ( drug1 ) - induced drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      42 : 
        {
          1 : "NN conj NNS nmod VBN acl NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj inhibitors nmod associated acl *drug0*"
            }
          4 : 
            {
              1 : "drug1 associated with cyclooxygenase-2 selective inhibitors and drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      43 : 
        {
          1 : "NN conj NN nmod NN conj NN conj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 conj ponv nmod history conj gender conj *drug0*"
            }
          4 : 
            {
              1 : "The frequency of PONV did not correlate to the amounts of drug1 , propofol , postoperative antiemetics consumed , or to female gender , non-smoking status , and history of PONV or drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      44 : 
        {
          1 : "NN appos NN nmod VB xcomp VBN nsubjpass NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 appos example nmod contribute xcomp *suggested* nsubjpass exposure nmod drug0"
            }
          4 : 
            {
              1 : "Exposure to drug1 ( BZD ) during foetal life has been suggested to contribute to neonatal morbidity and some congenital malformations , for example , drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      45 : 
        {
          1 : "NN compound NNS nmod NNS nmod NN nmod NN dobj VBG acl NNS nmod NNS nmod VBN nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound controls nmod dysplasias nmod number nmod % dobj exhibiting acl animals nmod groups nmod *observed* nmod dose nmod drug0"
            }
          4 : 
            {
              1 : "An inverse trend was observed between dose and multiplicity of drug1 in all drug-treated groups ( P = 0.03 ) , with animals receiving 75 mg/kg 5-ASA exhibiting 56 % of the number of dysplasias of the AOM / drug2 controls ( mean + / - SEM : 7.6 + / - 1.4 and 13.6 + / - 2.7 , respectively ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      46 : 
        {
          1 : "NN dep NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep *model* nmod drug0"
            }
          4 : 
            {
              1 : "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of drug1 ( AOM ) / dextran sulfate sodium ( DSS ) - induced drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      47 : 
        {
          1 : "NN nmod JJ nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod *common* nsubj treatment compound drug0"
            }
          4 : 
            {
              1 : "drug1 ( IMD ) treatment is now common in drug2 ( MS ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      48 : 
        {
          1 : "NN nmod NN nmod NN nmod NN conj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod therapy nmod *safety* nmod clarithromycin conj dexamethasone appos drug0"
            }
          4 : 
            {
              1 : "This trial determined the safety and efficacy of the combination regimen clarithromycin ( Biaxin ) , lenalidomide ( Revlimid ) , and dexamethasone ( drug1 ) as first-line therapy for drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      49 : 
        {
          1 : "NN compound NN nmod VBZ nsubj NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound proliferation nmod *has* nsubj drug0"
            }
          4 : 
            {
              1 : "In ER + breast tumors , 2.5 mg/d drug1 given for 14 days has no significant effect on drug2 cell proliferation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      50 : 
        {
          1 : "NN nsubj VBZ nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nsubj *has* nmod drug0"
            }
          4 : 
            {
              1 : "In drug1 , 2.5 mg/d drug2 given for 14 days has no significant effect on tumor cell proliferation . "
            }
          5 : 
            {
              1 : 1
            }
        }
      51 : 
        {
          1 : "NN dep NNS nmod NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep *dysplasias* nmod model nmod drug0"
            }
          4 : 
            {
              1 : "5-aminosalicylic acid inhibits colitis-associated colorectal dysplasias in the mouse model of drug1 / dextran sulfate sodium-induced drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      52 : 
        {
          1 : "NN nmod JJ nmod VBZ nsubj NN compound NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod complete nmod *results* nsubj therapy compound drug0"
            }
          4 : 
            {
              1 : "drug1 ( Biaxin [ clarithromycin ] / Revlimid [ lenalidomide ] / dexamethasone ) combination therapy results in high complete - and overall-response rates in treatment-naive symptomatic drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      53 : 
        {
          1 : "NN dobj VBG acl NNS nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj receiving acl patients nmod *drug0*"
            }
          4 : 
            {
              1 : "Recently , there have been reports of drug1 in patients receiving drug2 for a variety of diseases . "
            }
          5 : 
            {
              1 : 1
            }
        }
      54 : 
        {
          1 : "NN compound NNS dep NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 compound patients dep *development* nmod drug0"
            }
          4 : 
            {
              1 : "Development of sarcoidosis in drug1 - treated drug2 patients . "
            }
          5 : 
            {
              1 : 1
            }
        }
      55 : 
        {
          1 : "NN nmod NN conj CD root : punct : punct JJ root IN dep CD dep NNS nmod NN dobj VBD nsubj NN nmod NN"
          2 : 1
          3 : 
            {
              1 : "drug0 nmod burden conj 0.0 root - punct / punct drug-treated root for dep 0.0 dep dysplasias nmod multiplicity dobj *decreased* nsubj administration nmod drug0"
            }
          4 : 
            {
              1 : "Administration of 75 mg/kg drug1 decreased both the mean multiplicity of flat dysplasias ( 1.8 + / - 0.4 for drug-treated versus 5.6 + / - 1.2 for AOM/DSS control ) and the burden of drug2 ( tumor burden : 6.7 + / - 2.7 for drug-treated versus 14.9 + / - 3.9 units for AOM/DSS controls ) significantly ( P = 0.002 and 0.04 , respectively ) . "
            }
          5 : 
            {
              1 : 1
            }
        }
      56 : 
        {
          1 : "NN dep NN dep NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dep *model* dep sodium appos drug0"
            }
          4 : 
            {
              1 : "The chemopreventive activity of 5-ASA was evaluated in the Swiss Webster model of azoxymethane ( AOM ) / dextran sulfate sodium ( drug1 ) - induced drug2 . "
            }
          5 : 
            {
              1 : 1
            }
        }
      57 : 
        {
          1 : "NN dobj VB nsubj NN appos NN"
          2 : 1
          3 : 
            {
              1 : "drug0 dobj *control* nsubj dipropionate appos drug0"
            }
          4 : 
            {
              1 : "We tested the hypothesis that oral beclomethasone dipropionate ( drug1 ) would control drug2 ( GVHD ) in patients with anorexia , vomiting , and diarrhea . "
            }
          5 : 
            {
              1 : 1
            }
        }
    }
}